SCI Pharmtech Inc
TWSE:4119
SCI Pharmtech Inc
Operating Income
SCI Pharmtech Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Operating Income
NT$159.9m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-5%
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Operating Income
NT$1.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
9%
|
CAGR 10-Years
5%
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Operating Income
NT$701.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
100%
|
CAGR 10-Years
9%
|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Operating Income
NT$446.4m
|
CAGR 3-Years
22%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-6%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Operating Income
NT$5.1B
|
CAGR 3-Years
30%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Operating Income
NT$1.4B
|
CAGR 3-Years
19%
|
CAGR 5-Years
24%
|
CAGR 10-Years
15%
|
|
SCI Pharmtech Inc
Glance View
SCI Pharmtech Corp. is engaged in the biotechnology and medical care industry. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2002-08-12. The firm's main products include APIs, API intermediates and special and precision chemicals. The firm distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others
See Also
What is SCI Pharmtech Inc's Operating Income?
Operating Income
159.9m
TWD
Based on the financial report for Sep 30, 2024, SCI Pharmtech Inc's Operating Income amounts to 159.9m TWD.
What is SCI Pharmtech Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-5%
Over the last year, the Operating Income growth was -16%. The average annual Operating Income growth rates for SCI Pharmtech Inc have been -22% over the past three years , -26% over the past five years , and -5% over the past ten years .
You don't have any saved screeners yet